(IN BRIEF) BioNTech agreed to buy CureVac in an all-stock deal valuing CureVac at ~$1.25 billion, exchanging each share for $5.46 in BioNTech ADSs—a 55% premium to its recent stock price. The merger, expected to close in 2025, strengthens BioNTech’s … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged 2025 closing, ADSs, Alexander Zehnder, all-stock acquisition, American depositary shares, BioNTech, BNT327, Cancer Immunotherapy, CureVac, delivery formulations, dievini Hopp BioTech, integration plan, KfW, merger premium, mRNA, mRNA manufacturing, oncology strategy, pan-tumor programs, partnership, regulatory approvals, transformational therapies, Tübingen subsidiary, Ugur Sahin
(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged anti-CD30, Brentuximab Vedotin, Cancer Immunotherapy, cancer research, combination treatment, ICB resistance, immune checkpoint blockade, immunotherapy breakthroughs, lung cancer, melanoma, metastatic cancer, Newcastle University, pancreatic cancer, PD-1, skin cancer, solid tumors, T regulatory cells
(IN BRIEF) Scientists at the University of Southampton have engineered a new type of super-strong antibody, which could significantly enhance immune system responses in cancer patients. By altering the shape and rigidity of antibodies, the team discovered that these modified … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged antibodies, antibody engineering, Cancer Immunotherapy, Cancer Research UK, cancer treatment, disulfide bonds, immune response, immune system, immunotherapy, Isabel Elliott, Ivo Tews, Mark Cragg, Nature Communications, rigid antibodies, structural biology, super-strong antibody, University of Southampton
Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, announced that their combination treatment … Read the full press release
Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BÂLE, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionnier mondial des produits pharmaceutiques et des diagnostics axé sur l’avancement de la science pour améliorer la vie des … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged atezolizuma, Avastin®, bevacizumab, cancer du foie, Cancer Immunotherapy, carcinome hépatocellulaire à un stade précoce, CHC, early-stage hepatocellular carcinoma, étude IMbrave050, HCC, IMbrave050 study, immunothérapie anticancéreuse, Levi Garraway M.D. Ph.D., liver cancer, Roche, Tecentriq®
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer Immunotherapy, chemotherapy, FDA, Levi Garraway, lung cancer, non-small cell lung cancer, NSCLC, Real-Time Oncology Review, Roche, sBLA, supplemental Biologics License Application, Tecentriq®, treatment, tumours
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of care Application approved … Read the full press release
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Alecensa®, alectinib, anaplastic lymphoma kinase, ASCO virtual newsroom, ASCO20 Virtual Scientific Program, atezolizumab, cancer care, Cancer Immunotherapy, clinical data tiragolumab, Levi Garraway M.D. Ph.D., lung cancer, Roche, Tecentriq®
Second FDA Breakthrough Therapy Designation for MPDL3280A following bladder cancer in 2014 BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received a second Breakthrough Therapy Designation from the United States Food and … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?